Patents by Inventor Paul Stephen Donnelly

Paul Stephen Donnelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220041608
    Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
    Type: Application
    Filed: March 10, 2021
    Publication date: February 10, 2022
    Applicant: Clarity Pharmaceuticals Ltd
    Inventors: Nicholas Alan ZIA, Paul Stephen DONNELLY
  • Publication number: 20210363161
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Application
    Filed: August 4, 2021
    Publication date: November 25, 2021
    Inventors: Paul Stephen DONNELLY, Michelle Therese MA, Denis Bernard SCANLON
  • Patent number: 11123316
    Abstract: The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: September 21, 2021
    Assignee: The University of Melbourne
    Inventors: Paul Stephen Donnelly, Stacey Erin Rudd, Spencer John Williams
  • Patent number: 11111254
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: September 7, 2021
    Assignee: The University of Melbourne
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • Patent number: 10975089
    Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: April 13, 2021
    Assignee: Clarity Pharmaceuticals Ltd
    Inventors: Nicholas Alan Zia, Paul Stephen Donnelly
  • Publication number: 20210030900
    Abstract: The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The compounds work via a pre-targeting imaging approach in which the tetrazine reacts via click chemistry with a functional group such as a transcyclooctene which is pre-bound to a ligand such as a tumour specific antibody.
    Type: Application
    Filed: April 11, 2019
    Publication date: February 4, 2021
    Inventors: Paul Stephen Donnelly, Nicholas Alan Zia
  • Patent number: 10870664
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: December 22, 2020
    Assignee: The University of Melbourne
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • Publication number: 20200246286
    Abstract: The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.
    Type: Application
    Filed: April 8, 2020
    Publication date: August 6, 2020
    Inventors: Paul Stephen DONNELLY, Stacey Erin RUDD, Spencer John WILLIAMS
  • Patent number: 10653649
    Abstract: The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: May 19, 2020
    Assignee: The University of Melbourne
    Inventors: Paul Stephen Donnelly, Stacey Erin Rudd, Spencer John Williams
  • Publication number: 20200115391
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 16, 2020
    Inventors: Paul Stephen DONNELLY, Michelle Therese MA, Denis Bernard SCANLON
  • Publication number: 20200095257
    Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
    Type: Application
    Filed: June 5, 2018
    Publication date: March 26, 2020
    Applicant: THE UNIVERSITY OF MELBOURNE
    Inventors: Nicholas Alan ZIA, Paul Stephen DONNELLY
  • Patent number: 10544164
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: January 28, 2020
    Assignee: The University of Melbourne
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • Publication number: 20200009090
    Abstract: The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.
    Type: Application
    Filed: July 15, 2019
    Publication date: January 9, 2020
    Inventors: Paul Stephen DONNELLY, Stacey Erin RUDD, Spencer John WILLIAMS
  • Patent number: 10398660
    Abstract: The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal center, particularly for the imaging of tumors.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: September 3, 2019
    Assignee: The University of Melbourne
    Inventors: Paul Stephen Donnelly, Stacey Erin Rudd, Spencer John Williams
  • Publication number: 20190225625
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Application
    Filed: April 9, 2019
    Publication date: July 25, 2019
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • Patent number: 10301326
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilizing the radiolabelled compounds of the invention.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: May 28, 2019
    Assignee: THE UNIVERSITY OF MELBOURNE
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • Publication number: 20190099392
    Abstract: The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.
    Type: Application
    Filed: April 26, 2018
    Publication date: April 4, 2019
    Inventors: Paul Stephen Donnelly, Stacey Erin Rudd, Spencer John Williams
  • Patent number: 9980930
    Abstract: The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: May 29, 2018
    Assignee: The University of Melbourne
    Inventors: Paul Stephen Donnelly, Stacey Erin Rudd, Spencer John Williams
  • Publication number: 20170326084
    Abstract: The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.
    Type: Application
    Filed: October 16, 2015
    Publication date: November 16, 2017
    Inventors: Paul Stephen DONNELLY, Stacey Erin RUDD, Spencer John WILLIAMS
  • Publication number: 20170267698
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Application
    Filed: June 2, 2017
    Publication date: September 21, 2017
    Inventors: Paul Stephen DONNELLY, Michelle Therese Ma, Denis Bernard Scanlon